Search tips
Search criteria 


Logo of gutGutView this articleSubmit a manuscriptReceive email alertsContact usBMJ
Gut. 1991 September; 32(9): 1061–1065.
PMCID: PMC1379051

Ursodeoxycholic acid in chronic liver disease.


The hydrophilic bile acid ursodeoxycholic acid has recently been shown to reduce biochemical markers of both cholestasis and hepatocellular damage in patients with chronic liver diseases. The most compelling evidence available is for chronic cholestatic liver diseases, in particular primary biliary cirrhosis, primary sclerosing cholangitis, and cholestasis associated with cystic fibrosis. The effects may be less beneficial in patients with advanced liver disease from these conditions. Data from placebo controlled trials are now available in support of earlier uncontrolled observations, but it is not yet clear whether short term benefit results in an improvement in longterm prognosis. The mechanism of action of the compound seems to reside in its displacement of toxic hydrophobic bile acids from both the bile acid pool and hepatocellular membranes. There may be an independent effect on bile flow, which could be of particular importance in cystic fibrosis, and possibly an effect on the immune system. Ursodeoxycholic acid should now be regarded as occupying a central place in the medical management of chronic cholestatic liver diseases, in particular primary biliary cirrhosis, because it improves cholestasis and reduces hepatocellular damage and it is not toxic. Research should now be targeted on whether treatment with ursodeoxycholic acid, initiated early in cholestatic liver conditions, improves the long-term outcome.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hübner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig Dis Sci. 1985 Jul;30(7):642–649. [PubMed]
  • Hofmann AF, Popper H. Ursodeoxycholic acid for primary biliary cirrhosis. Lancet. 1987 Aug 15;2(8555):398–399. [PubMed]
  • Triger DR. Update on primary biliary cirrhosis. Dig Dis. 1990;8(2):61–70. [PubMed]
  • Kaplan MM. Medical treatment of primary biliary cirrhosis. Semin Liver Dis. 1989 May;9(2):138–143. [PubMed]
  • Graham JM, Northfield TC. Solubilization of lipids from hamster bile-canalicular and contiguous membranes and from human erythrocyte membranes by conjugated bile salts. Biochem J. 1987 Mar 15;242(3):825–834. [PubMed]
  • Poupon R, Chrétien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet. 1987 Apr 11;1(8537):834–836. [PubMed]
  • Bateson MC, Ross PE, Diffey BL. Ursodeoxycholic acid in primary biliary cirrhosis. Lancet. 1989 Apr 22;1(8643):898–899. [PubMed]
  • Matsuzaki Y, Tanaka N, Osuga T, Aikawa T, Shoda J, Doi M, Nakano M. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am J Gastroenterol. 1990 Jan;85(1):15–23. [PubMed]
  • Leuschner U, Fischer H, Kurtz W, Güldütuna S, Hübner K, Hellstern A, Gatzen M, Leuschner M. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology. 1989 Nov;97(5):1268–1274. [PubMed]
  • Poupon RE, Eschwège E, Poupon R. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group. J Hepatol. 1990 Jul;11(1):16–21. [PubMed]
  • Vogel W, Kathrein H, Judmaier G, Braunsteiner H. Deterioration of primary biliary cirrhosis during treatment with ursodeoxycholic acid. Lancet. 1988 May 21;1(8595):1163–1163. [PubMed]
  • Chazouillères O, Poupon R, Capron JP, Metman EH, Dhumeaux D, Amouretti M, Couzigou P, Labayle D, Trinchet JC. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol. 1990 Jul;11(1):120–123. [PubMed]
  • Cotting J, Lentze MJ, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut. 1990 Aug;31(8):918–921. [PMC free article] [PubMed]
  • Thompson JN, Cohen J, Blenkharn JI, McConnell JS, Barr J, Blumgart LH. A randomized clinical trial of oral ursodeoxycholic acid in obstructive jaundice. Br J Surg. 1986 Aug;73(8):634–636. [PubMed]
  • Ullrich D, Rating D, Schröter W, Hanefeld F, Bircher J. Treatment with ursodeoxycholic acid renders children with biliary atresia suitable for liver transplantation. Lancet. 1987 Dec 5;2(8571):1324–1324. [PubMed]
  • Nittono H, Tokita A, Hayashi M, Nakatsu N, Obinata K, Watanabe T, Yamashiro Y, Yabuta K, Miyano T. Ursodeoxycholic acid in biliary atresia. Lancet. 1988 Mar 5;1(8584):528–528. [PubMed]
  • Nittono H, Tokita A, Hayashi M, Watanabe T, Obinata K, Nakatsu N, Miyano T. Ursodeoxycholic acid therapy in the treatment of biliary atresia. Biomed Pharmacother. 1989;43(1):37–41. [PubMed]
  • Bircher J. Treatment of patients with benign recurrent intrahepatic cholestasis. Hepatology. 1989 Dec;10(6):1030–1032. [PubMed]
  • Bellentani S, Tabarroni G, Barchi T, Ferretti I, Fratti N, Villa E, Manenti F. Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gamma-glutamyltranspeptidase serum levels in patients with hypertransaminasemia. Results from a double-blind controlled trial. J Hepatol. 1989 Jan;8(1):7–12. [PubMed]
  • Kitani K, Kanai S. Tauroursodeoxycholate prevents taurocholate induced cholestasis. Life Sci. 1982 Feb 7;30(6):515–523. [PubMed]
  • Kitani K, Kanai S. Interactions between different bile salts in the biliary excretion of the rat. Res Commun Chem Pathol Pharmacol. 1983 Jan;39(1):139–152. [PubMed]
  • Chretien Y, Poupon R, Gherardt MF, Chazouilleres O, Labbe D, Myara A, Trivin F. Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment. Gut. 1989 Aug;30(8):1110–1115. [PMC free article] [PubMed]
  • Batta AK, Salen G, Arora R, Shefer S, Tint GS, Abroon J, Eskreis D, Katz S. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. Hepatology. 1989 Oct;10(4):414–419. [PubMed]
  • Stiehl A, Rudolph G, Raedsch R, Möller B, Hopf U, Lotterer E, Bircher J, Fölsch U, Klaus J, Endele R, et al. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology. 1990 Sep;12(3 Pt 1):492–497. [PubMed]
  • Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology. 1990 Jan;11(1):12–15. [PubMed]
  • Podda M, Ghezzi C, Battezzati PM, Bertolini E, Crosignani A, Petroni ML, Zuin M. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig Dis Sci. 1989 Dec;34(12 Suppl):59S–65S. [PubMed]
  • Balasubramaniam K, Grambsch PM, Wiesner RH, Lindor KD, Dickson ER. Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology. 1990 Jun;98(6):1567–1571. [PubMed]

Articles from Gut are provided here courtesy of BMJ Publishing Group